TICKERNERD
Menu
VNRXVNRXHealthcare · Medical Devices

VNRX Stock Forecast: VolitionRX Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.22
−4.61% on the day

The 5 Wall Street analysts covering VolitionRX Ltd. hold a median 12-month price target of $20 — +9015.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$6.9M
Ticker Nerd rank
44 / 100
Median analyst target
$20
Analysts covering
5
Revenue$399K−2.0% y/y
Operating income−$4.2M
Net income−$7.3M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.6%
1M
−33.5%
YTD
−95.8%
1Y
−98.3%
From 52W high
−98.3%
From 52W low
0.0%
$0
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VNRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VolitionRX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
77
Growth
76
Revisions
71
Volatility
59
Quality
19
Momentum
19
Value
18
Issuance
9

Size (95): Smaller than most of the companies we track.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VNRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26VNRXHigh $24Median $20Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $2Median $20High $24

The green dot is the last close — the median target sits +9015.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Apr 2026D. Boral CapitalDowngradeHold—
2 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
9 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
3 Dec 2025Maxim GroupDowngradeHold—
26 Nov 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Freedom BrokerMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
29 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VNRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VNRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, VolitionRX Ltd. returned −98.3% against +16.2% for the S&P 500, dividends included.

VNRX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26VNRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VNRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

VolitionRX Ltd. (VNRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
2.8×

Cheaper than 43% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−2.0%

Higher than 24% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1042.5%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
65.6%

Higher than 94% of US stocks

Return on assets
−142.9%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

VolitionRX Ltd. (VNRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • VolitionRX Ltd. has a market value of $6.9M and an enterprise value of $10.3M.

  • Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter shrank 2.0% year on year.

  • Net income over the same four quarters: −$25.7M, a −1046.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.6M.

  • Shares outstanding: 12.0M.

  • Trailing P/E: −0.1×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • VolitionRX Ltd. employs 57 people — $43K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

VNRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VNRXVolitionRX Ltd.$6.9M
44
AMIXAutonomix Medical, Inc.$6.1M
10
NVNOenVVeno Medical Corp.$5.7M
36
WOKWORK Medical Technology Group Ltd.$6.8M
16
INBSIntelligent Bio Solutions, Inc.$5.2M
15
VVOSVivos Therapeutics, Inc.$5.0M
28
AIDX20/20 Biolabs, Inc.$4.6M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VolitionRX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VNRX news & analysis

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

PRNewsWire · 17 Sept 2026positive

VolitionRx shared further details and a video about the official launch of the Government-funded DETECSEPS Consortium in France, which focuses on early detection of sepsis. The announcement provides additional information about the project's initiation.

Why it matters — A VNRX watcher would care because this marks progress in Volition's participation in a government-funded consortium addressing sepsis early detection in France.

VolitionRx Participates in Launch of DETECSEPS Program in France

PRNewsWire · 17 Sept 2026positive

VolitionRx announced the official launch of the DETECSEPS program in France, a government-funded €6.3 million consortium focused on early sepsis detection. Volition's Nu.Q NETs assay was selected as the sole biomarker for France's real-world evaluation of early sepsis detection.

Why it matters — This selection positions Volition's Nu.Q NETs assay as the only biomarker in a French government-funded consortium, potentially broadening its clinical and commercial visibility in sepsis detection.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

PRNewsWire · 14 Sept 2026positive

VolitionRx Limited announced the full pre-payment in cash of the outstanding balance on its $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC, which was due May 20, 2027.

Why it matters — Fully paying off the convertible note in cash eliminates a potential conversion-related equity overhang on VNRX's shares.

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

PRNewsWire · 10 Sept 2026positive

Volition presented early-stage data on Stage I solid cancer detection at the ESMO MAP Conference. The company highlighted a $36 billion total addressable market in early cancer detection and minimal residual disease.

Why it matters — The presentation advances Volition's early cancer detection pipeline, which could broaden its addressable market beyond its current focus.

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

Benzinga · 27 Aug 2026positive

VolitionRx reported a 112% year-over-year revenue increase in the first half of 2026, reaching $1.4 million, as the diagnostics company expanded its clinical and commercial operations. The news was accompanied by a surge in the company's stock on Thursday.

Why it matters — A VNRX watcher would care because strong revenue growth and expanded clinical and commercial operations point to the company broadening its addressable markets and validating its diagnostics platform.

FAQ

Frequently asked questions about VNRX stock

What is the VNRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering VolitionRX Ltd. have a median 12-month price target of $20, with estimates ranging from $2 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNRX stock a buy right now?

Of the 5 analysts covering VolitionRX Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VolitionRX Ltd. 44 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNRX?

As at 8 Oct 2026, VolitionRX Ltd. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will VNRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +9015.8% from the last close, and Ticker Nerd's factor model ranks VolitionRX Ltd. 44 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNRX stock forecast for 2030?

No analyst covering VolitionRX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $24 over the next 12 months.

How has VNRX stock performed over the past year?

VolitionRX Ltd. returned -98.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VolitionRX Ltd. do?

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.

What is the latest news on VNRX?

The most recent item we track (PRNewsWire, 17 Sept 2026): "VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France". VolitionRx shared further details and a video about the official launch of the Government-funded DETECSEPS Consortium in France, which focuses on early detection of sepsis. The announcement provides additional information about the project's initiation.

Company

About VolitionRX Ltd.

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis. The company also offers veterinary applications such as Nu.Q Vet and research tools such as Nu.Q Discover, alongside technologies designed to support earlier disease detection and treatment monitoring. VolitionRx Limited serves healthcare and life sciences markets across the United States, Europe, and Asia from its headquarters in Henderson, Nevada.

CEO Mr. Cameron Reynolds MBA · 57 employees · United States · https://volition.com